Trigan-D

Quick links to important sections

Trigan-D

Selected form

Method of action: Analgesic, Antispasmodic

Treatment option: Pain, Colic, Neuralgia, Renal Colic

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trigan-D

Property Description
Active Ingredients Acetaminophen (Paracetamol), Dicycloverine (Dicyclomine)
Form Oral tablet
Pharmacological Class Antispasmodic and Analgesic (Dual-action)
Primary Action Relaxation of smooth muscle combined with pain signal reduction
Origin Synthetic combination drug

Trigan-D: Classification and Core Identity

Trigan-D is a brand name for a synthetic fixed-dose combination medication administered as an oral tablet, frequently utilized as an Antispasmodic and Analgesic agent. This formulation is distinctive because it is applied in scenarios where general discomfort is linked to or complicated by involuntary muscular cramping (visceral pain), a therapeutic application clinically recognized for efficacy in managing such spasmodic conditions.

This structure allows the drug to deliver two different pharmacological approaches simultaneously, distinguishing it from single-ingredient pain relievers. The medicine's identity as a dual-action solution means it is specifically formulated to address both the symptom (pain) and a significant physical source of that discomfort (smooth muscle spasm).

Active Ingredients and Pharmacological Class

The efficacy of Trigan-D is derived from its two core active chemical entities: Acetaminophen (Paracetamol) and Dicycloverine (Dicyclomine). Acetaminophen contributes analgesic and antipyretic qualities. Dicycloverine supplies the potent antispasmodic action, which operates primarily by blocking muscarinic receptors on smooth muscles to mitigate painful contractions.

This combination utilizes the different biological pathways targeted by each ingredient: Acetaminophen acts centrally to reduce pain signals, while Dicycloverine acts peripherally to directly influence smooth muscle tissue. The medicine helps ease discomfort by specifically targeting and relaxing the tensed muscles that cause sharp cramping.

General Purpose: Dual Relief for Visceral Cramping

The primary purpose of Trigan-D is to provide targeted relief from pain where discomfort is intensified by involuntary muscular spasms or visceral cramping. By leveraging the muscle-relaxing properties of Dicycloverine and the pain-reducing effects of Acetaminophen, the drug addresses both the underlying physical cause of cramping and the patient’s overall sensation of pain. This ensures the medicine is fundamentally intended for pain states defined by a component of intense, involuntary muscle contraction.

What side effects are possible with Trigan-D?

Possible Side Effects and Safety Information

The following summary outlines the officially documented side effects and safety constraints for Trigan-D, based on regulatory information.

Adverse Reactions by Frequency

Side effects are categorized by how often they may occur, as defined in official prescribing information:

Frequency Examples of Listed Adverse Reactions
Common (up to 1 in 10 people) Nausea, Vomiting, Dry mouth, Constipation, Dizziness, Drowsiness, Blurred vision.
Uncommon (up to 1 in 100 people) Fast heart rate, Difficulty in urination, Skin rash or itching.
Rare / Very Rare Confusion, Hallucinations, Glaucoma (increased pressure in the eye).

Adverse reactions may affect several System-Organ Classes, including the Gastrointestinal System, Nervous System, Skin, and the Eyes.

Serious Safety Information and Restrictions

Serious Reactions: Officially highlighted serious adverse reactions include signs of a severe allergic reaction (requiring immediate medical attention and discontinuation of the drug), and the risk of liver damage associated with overdose or use in patients with severe liver disease. Glaucoma is also documented as a very rare, serious risk.

Population-Specific Constraints: The drug is generally not recommended during pregnancy or breastfeeding due to documented risks. Caution is necessary for older adults due to increased susceptibility to effects like confusion. Use is contraindicated or requires extreme caution in patients with severe liver impairment or severe kidney impairment.

Contraindications (Restrictions): The medication is restricted in patients with specific pre-existing conditions. These include Glaucoma, Myasthenia gravis, Obstructive uropathy (urinary tract blockage), Obstructive disease of the gastrointestinal tract, Severe ulcerative colitis, and Severe liver disease. Patients are advised that the medication may cause dizziness or drowsiness, which can impair the ability to drive or operate machinery.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Trigan-D (Acetaminophen / Dicycloverine) addresses the distinct toxicological risks posed by its two components, as documented by government regulatory sources.

Documented Overdose Scope

Property Official Regulatory Documentation
Documented Overdose Presentations Acetaminophen component: Nausea, vomiting, diaphoresis, and general malaise, preceding the delayed risk of hepatic necrosis. Dicycloverine component: Anticholinergic signs including tachycardia, mydriasis, blurred vision, dry mouth, confusion, agitation, and urinary retention. Severe toxicity may lead to CNS depression, coma, or respiratory failure.
Physiological Systems Affected Hepatic, Cardiovascular, Central Nervous System, and Renal systems.
Population-specific Overdose Notes Increased risk of severe hepatotoxicity is documented in patients with pre-existing hepatic impairment or chronic alcohol consumption. Increased CNS sensitivity to anticholinergic effects is noted in pediatric and elderly patients.
Emergency-response statements Seek immediate medical attention and contact a Poison Control Center or emergency services immediately for any suspected overdose.
When immediate medical help is required Urgent medical attention is required to assess the risk of delayed hepatic necrosis and manage acute anticholinergic effects, including potential circulatory or respiratory compromise.

Official Overdose Statements

  • The life-threatening risk of hepatic necrosis is the most serious consequence documented from the Acetaminophen component, often delayed in its clinical presentation.
  • N-acetylcysteine is the specific antidote documented for Acetaminophen toxicity, and its administration is an officially required emergency procedure.
  • Hospital monitoring for a minimum of 24 hours and frequent measurement of liver function tests are officially required procedures.
  • Overdose management for all other effects is designated as symptomatic and supportive.

Therapeutic Uses of Trigan-D

What Trigan-D Treats: Main Uses and Benefits

Trigan-D is commonly used in situations involving certain distressing symptoms where spasms and cramping are the main sources of physical discomfort. This medication is applied across therapeutic domains where additional symptomatic support is needed to manage acute symptom clusters. The primary role of the medication is to provide supportive relief, which is relevant for easing distress during difficult episodes of acute pain.

The medication is used to help manage symptoms related to conditions such as renal colic, biliary colic, severe intestinal spasms, and painful menstruation (dysmenorrhea). This therapeutic approach is relevant for easing pain associated with smooth muscle spasms in the gastrointestinal and urogenital systems.

Therapeutic Benefit

“The medication helps address symptom clusters that may become intense or disruptive, and may assist with easing physical strain during symptomatic periods.”

The medicine is also applied in scenarios where patients experience related discomfort, such as an associated fever, and may contribute to easing the overall symptom load.

Quick Fact

Quick Fact: Relief for Spasmodic Pain and Fever

Eligibility and Restrictions for Use

Trigan-D is not suitable for all individuals. Official regulatory documents define specific populations and conditions where use is either contraindicated (prohibited) or requires special caution.

Contraindicated Populations

The medicine is formally contraindicated for use in patients with known hypersensitivity or allergy to its active ingredients (Paracetamol and Dicyclomine). It must also not be used in individuals with:

  • Obstructive conditions: Obstructive disease of the gastrointestinal or urinary tract, or obstructive uropathy.
  • Eye and muscle disorders: Glaucoma or Myasthenia Gravis.
  • Severe organ damage: Severe active liver disease or kidney diseases associated with excessive painkiller use (Analgesic Nephropathy).

Restricted or Cautionary Use

Age and Physiological States:

  • Use is generally not recommended for children below 12 years of age, as safety and efficacy have not been established.
  • It is generally avoided or not recommended for women who are breastfeeding as components may pass into human milk.
  • Use in pregnancy requires medical consultation, as safety has not been definitively established.
  • Older adults/Geriatric patients require careful use due to increased susceptibility to potential side effects.

Condition-Specific Restrictions:

Caution is advised and use may be restricted for patients with a history of severe liver or kidney disease, prostatic hypertrophy (enlarged prostate), unstable cardiovascular conditions (including coronary heart disease or congestive heart failure), and specific gastrointestinal disorders such as severe ulcerative colitis or reflux esophagitis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns based on regulatory labeling for Trigan-D’s active components, Acetaminophen (Paracetamol) and Dicycloverine (Dicyclomine).

Anticholinergic and Pharmacodynamic Interactions

Co-administration with Antiglaucoma Agents is strictly contraindicated because Dicycloverine may antagonize their effect, which could increase intraocular pressure. The simultaneous use of Dicycloverine with other agents that have anticholinergic properties, such as MAO Inhibitors, Narcotic Analgesics, and Antipsychotic Agents, may result in additive effects, potentially increasing certain actions or side effects. Furthermore, Dicycloverine may antagonize the effects of drugs that alter gastrointestinal motility, such as Metoclopramide.

Pharmacokinetic and Timing Requirements

The anticholinergic component may alter gastrointestinal absorption, which could lead to an increased serum concentration of co-administered medicines, notably slowly dissolving dosage forms of Digoxin. Antacids should not be administered simultaneously as they may interfere with the absorption of Dicycloverine, an interaction that necessitates separation of timing.

Metabolic and Substance Interactions

Substances that induce or regulate the CYP2E1 enzyme may alter the metabolism of Acetaminophen and increase its hepatotoxic potential. The regulatory label advises caution regarding the Acetaminophen component in cases of chronic alcoholism due to an increased risk of liver injury. Additionally, the maximum daily dose of Acetaminophen is cumulative and includes exposure from all other Acetaminophen-containing products.

Mechanism of Action

The pharmacological function relies on a dual, complementary mechanism involving two distinct active components. This mechanism modulates both the physical state of smooth muscle and the central pathways of nociception, leading to an integrated physiological consequence.

Modulation of Smooth Muscle Cholinergic Signaling

The Dicycloverine component acts peripherally by competitively blocking Muscarinic Acetylcholine Receptors (M3 subtype) on smooth muscle cells. This inhibition prevents the neurotransmitter acetylcholine from initiating the cascade that causes the muscle to contract, resulting in a decrease in smooth muscle tone and peristaltic activity within relevant organ systems, such as the gastrointestinal tract.

Central Nociceptive Pathway Dampening

The Acetaminophen component exerts its action centrally by inhibiting the enzyme Cyclooxygenase (COX) within the spinal cord and brain. This mechanism limits the synthesis of prostaglandins ( PGE2), which are compounds that modulate central nociceptive signaling. Additionally, it potentiates the descending inhibitory pathways, resulting in a raised nociceptive threshold at the central level and modulation of supraspinal signal processing.

Dosage and Administration Information

How to Use Trigan-D: Official Administration Guidelines

Trigan-D is a combination product typically formulated as an oral tablet containing Dicyclomine and Paracetamol (also known as Acetaminophen). This section details the proper administration strictly based on official regulatory documentation.


Administration Requirements

Instruction Component Official Guideline
Route of Administration Oral (by mouth) only.
Dosing Schedule (Adults) One tablet, taken up to four times a day (q.i.d.). The exact dose and duration are determined by a physician.
Administration Method Swallow the tablet whole with a full glass of water. Do not crush, chew, or break the tablet, as this may affect the drug's intended release.
Timing in Relation to Meals May be taken with or without food.

Procedural Rules

  • Maximum Daily Dose: Do not exceed the prescribed total daily dose, especially for the Paracetamol component, to mitigate the risk of severe liver damage.
  • Missed Dose: If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, skip the missed one and continue the regular schedule. Do not double the dose to make up for the one that was missed.
  • Age Restrictions: The use of Trigan-D tablets is not recommended for children below 12 years of age.
  • Special Populations: Caution is advised and dose adjustment may be necessary for elderly patients and those with severe kidney or liver impairment.

Recent Clinical Evidence

Research Evidence Overview of Studies for Trigan-D

Evidence for Use in Acute Visceral Colic

Research was studied for this application primarily through Randomized Controlled Trials (RCTs) and other active-comparator studies. These trials were conducted during periods of increased symptom activity and focused on adult patients in acute clinical settings. The research examined outcomes related to physical discomfort by monitoring the change in pain intensity and evaluating patient-reported outcomes describing perceived discomfort over periods of hours. Comparative studies data show patterns related to differences in outcomes monitored between the combination and other treatments evaluated.

Despite the available short-term data, the long-term effects are not fully established for this type of acute pain. The follow-up durations were limited to the acute pain phase itself, meaning that studies provide limited information for long-term outcomes or tracking the potential need for subsequent relief.

Evidence for Use in Functional Spasmodic Conditions

The research base that was studied for conditions characterized by fluctuating or episodic manifestations, such as functional gastrointestinal spasms (IBS) and painful menstruation (dysmenorrhea), includes older placebo-controlled trials and systematic reviews of the antispasmodic class. Studies were applied in research contexts involving fluctuating or unstable symptoms and adults experiencing recurrent pain. The research examined outcomes reflecting daily functioning or activity level, as well as patient-reported outcomes describing perceived discomfort over defined time intervals.

Academic reviews note that many of the core trials for the antispasmodic component were characterized by modest sample sizes and older methodologies. For these recurrent functional conditions, the evidence supporting the primary antispasmodic component may be categorized as having low certainty. Studies report how symptoms evolved in the observed populations over observation periods typically lasting two to eight weeks.

Examining Study Quality and Key Limitations

The evidence level for acute spasmodic conditions is Moderate, based on the presence of Randomized Controlled Trials and comparison studies. Conversely, the evidence for managing functional conditions appears to be less certain, with an evidence level categorized as Low. Long-term effects are not fully established, and data for certain groups remain insufficient, particularly for older adults. Research provides context but not individual predictions, and the data describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Trigan-D (FAQ)


Q: Does Trigan-D interact negatively with common cold and flu medicines?

A: Official product information warns that the Dicyclomine component, which has anticholinergic effects, may result in additive effects when combined with other medicines that also possess anticholinergic properties, including certain cold and flu remedies. Additionally, the Paracetamol component requires careful consideration, as taking it with other Acetaminophen-containing products may increase the cumulative risk of liver damage.

Q: Are there any vitamins or supplements that should be avoided while taking Trigan-D?

A: Regulatory information advises caution regarding potential interactions. For example, the anticholinergic component may increase the absorption of certain co-administered drugs. It is standard medical guidance to inform a healthcare provider about all concomitant medications, including herbal remedies and supplements, as their potential interactions are often not fully established in formal regulatory documents.

Q: Can someone with a history of kidney problems safely take Trigan-D?

A: Official warnings state that caution must be taken when this medicine is used by patients with impaired renal (kidney) function. Use requires careful consideration and monitoring. For severe kidney impairment, dosage adjustments or changes to the dosing interval may be necessary.

Q: Is Trigan-D safe for people with known liver issues?

A: According to official product information, this medicine is contraindicated (should not be used) in patients with severe active liver disease or severe hepatic (liver) impairment. For other forms of liver impairment, the drug's label advises caution.

Q: Why is Trigan-D often cautioned against for people with glaucoma?

A: Official documents state that the medicine is contraindicated for people with glaucoma. This is because the Dicyclomine component has anticholinergic properties that can potentially increase the pressure inside the eye (intraocular pressure) and reduce the effectiveness of anti-glaucoma medicines.

Q: Is Trigan-D used for the long-term management of conditions like IBS?

A: The safety and effectiveness of the Dicyclomine component have not been established for use at higher doses or for treatment periods longer than two weeks. The available safety and efficacy data primarily supports its use for short-term management of acute episodes of pain or spasm.

Q: Can Trigan-D interact with prescription medications for high blood pressure?

A: Official warnings advise that caution should be exercised in patients with hypertension (high blood pressure) or certain cardiovascular conditions. Dicyclomine has been observed to interact with certain blood pressure medications, such as thiazide diuretics, which may alter the risk of side effects.

Q: Can Trigan-D interact with medication used to treat depression or anxiety?

A: Official information indicates that caution is advised when using Dicyclomine with certain anti-depressants, such as MAO Inhibitors or SSRIs. This is due to the potential for additive anticholinergic side effects (like dry mouth or blurred vision), and caution is advised regarding the potential for worsening certain psychiatric symptoms.

Q: How does Trigan-D compare in action to purely anticholinergic medications?

A: Regulatory documents indicate that the Dicyclomine component has a dual mode of action: it works by both an anticholinergic effect and a direct effect on smooth muscle cells. Its anticholinergic potency is considered significantly less potent than that of atropine, a classic anticholinergic agent.

Q: Does Trigan-D help with general stomach ache or only pain caused by spasms?

A: The Dicyclomine component is specifically indicated to relieve smooth muscle spasm of the gastrointestinal tract. The medicine is primarily intended for pain states where the discomfort is caused by or linked to involuntary muscular cramping, such as in functional bowel conditions.

Q: Is there a risk of dependence or addiction with Trigan-D?

A: Official labeling for the Dicyclomine component states that abuse of and/or dependence on the drug, particularly for its anticholinergic effects, have been rarely reported.

Q: Is it safe to take Trigan-D if I am already taking a different pain reliever with paracetamol?

A: Official product information specifies that the maximum recommended daily dose of Acetaminophen (Paracetamol) includes Acetaminophen taken from all sources (including other medicines). Exceeding this total daily amount can lead to hepatic injury (liver damage), including the risk of liver failure and death. Information on all consumed products should be reviewed.

Q: Can Trigan-D be used for muscle spasms outside of the digestive tract?

A: The Dicyclomine component is indicated for the relief of functional bowel/irritable bowel syndrome and acts to relieve smooth muscle spasm of the gastrointestinal tract. The official product labeling is specifically focused on use for this system and does not provide information regarding efficacy or safety for muscle spasms outside of it.

Q: Does Trigan-D have any known effects on sleep quality?

A: Adverse events related to the Central Nervous System include insomnia (difficulty falling or staying asleep). It is also noted that drowsiness and sleepiness are commonly reported side effects of this medication.

Q: Can Trigan-D interact with any common antibiotics?

A: The Dicyclomine component is contraindicated in cases of diarrhea caused by severe bacterial infection (such as pseudomembranous enterocolitis), a condition that can sometimes be a complication following the use of broad-spectrum antibiotics.

Q: Is it true that Trigan-D can affect the body's ability to sweat and regulate temperature?

A: Regulatory warnings indicate that the drug has the potential to cause decreased sweating (known as anhidrosis). Because of this effect, especially when exposed to heat, there is an increased risk of developing fever and heat stroke.

How should Trigan-D be stored and disposed of?

How to Store and Dispose of Trigan-D?

Storage Requirements

Official regulatory labeling specifies that Trigan-D tablets must be stored at room temperature, typically below 30 C or 25 C, in a cool and dry place. The medicine must be kept in its original container and that container should remain tightly closed. It is mandatory to protect the tablets from direct sunlight, heat, and moisture. Always store Trigan-D out of the sight and reach of children and pets to prevent accidental exposure.

Disposal Instructions

Expired or unused Trigan-D should be disposed of in accordance with local regulations for pharmaceutical waste. The preferred method is using a community drug take-back program. If this is not available, the product must be rendered unusable by mixing it with an undesirable substance (such as dirt) and sealing it in a plastic bag before placing it in the household trash. Do not flush Trigan-D down the toilet or pour it down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trigan-D found in:

A-Z Index: